Article

New Treatment Offers Relief from Bone Marrow Disorder

Author(s):

Patients with myelofibrosis have few options for relief from an enlarged spleen, a side effect of the cancer, but there is hope on the horizon.

Patients with myelofibrosis, a rare type of slow-growing leukemia, have few options for relief from one of the most pernicious symptoms: an enlarged spleen, as well as low blood counts, which sometimes require transfusions. But a new study, coupled with results from a previous phase 3 study, shows significant benefit compared with available therapies.

Myelofibrosis is a disorder in which mutant blood stem cells disrupt the production of healthy blood cells, resulting in scarring of the normally spongy bone marrow. Because the compromised bone marrow cannot produce an adequate amount of blood cells, the liver and spleen try to make up for it, causing the organs to swell.

The condition affects about 3,000 people in the U.S. annually, with more than one-fourth of patients eventually developing bone marrow failure and anemia, as well as acute myeloid leukemia. All myelofibrosis patients have an autonomously activated Janus kinase (JAK) signaling pathway, which regulates blood cell production, and presents a target for cancer therapies.

In the recent randomized phase 3 study, researchers showed that ruxolitinib, a JAK inhibitor, delivered rapid, significant and lasting spleen-size reduction in patients, although it did not improve blood counts. After 24 weeks, 31.9 percent of 146 patients receiving the drug achieved 35 percent or greater reduction in spleen size compared with 0 percent of 73 patients receiving the best available therapy. Side effects of the therapy include anemia and thrombocytopenia.

"This therapy has the potential to significantly change the treatment landscape for these patients, and could greatly improve their outlook," says Alessandro Vannucchi, MD, of the University of Florence in Italy. "…We've urgently needed new treatments for this condition."

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of man with text.
Image of doctor with text.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
Dr. Breelyn Wilky stresses the importance of expert guidance and second opinions for patients with GIST, as treatment options continue to evolve rapidly.
Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.
An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns.
Image of woman with text.
Image of goy, and text.